APC promoter methylation is correlated with development and progression of bladder cancer, but not linked to overall survival: a meta-analysis

被引：8
作者：
Bai, Z. J. [1 ]
Liu, Q. [1 ]
Wang, X. S. [1 ]
Liu, W. Y. [2 ]
机构：
[1] Nankai Univ, Tianjin Cent Hosp 1, Dept Urol, Tianjin 300192, Peoples R China
[2] Tianjin Med Univ, Sch Basic Med Sci, Dept Pathogen Biol, Tianjin 300070, Peoples R China
来源：
NEOPLASMA | 2019年 / 66卷 / 03期
关键词：
APC; methylation; bladder cancer; urine; biomarker; prognosis; EPIGENETIC ALTERATIONS; UROTHELIAL CARCINOMA; DNA HYPERMETHYLATION; BLOOD-SAMPLES; VOIDED URINE; GENES; DIAGNOSIS; BIOMARKER; RASSF1A; FAP;
D O I：
10.4149/neo_2018_181009N753
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The clinical role of APC promoter methylation in patients with bladder cancer remains to be determined. The relevant databases (PubMed, EMBASE, EBSCO, WANFANG DATA, CNKI and Cochrane Library) were searched to get eligible studies. The overall odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs) were calculated to assess the effects of APC promoter methylation on bladder cancer risk and clinicopathological features. 2214 patients with bladder cancer and 665 controls were identified. APC promoter methylation was significantly higher in bladder cancer than in non-malignant tissue and urine samples (tissue: OR=11.14, 95% CI=4.29-28.91, p<0.001; urine: OR=24.31, 95% CI=6.26-94.38, p<0.001), but not in blood samples (p=0.242). The relationship was observed between APC promoter methylation and gender (male vs. female: OR=1.46, 95% CI=0.96-2.22, p=0.074), tumor stage (stage T2-T4 vs. Ta-T1: OR=3.00, 95% CI=1.66-5.42, p<0.001), and tumor grade (grade 3-4 vs. grade 1-2: OR=1.99, 95% CI=1.15-3.42, p=0.013). But no correlation was found between APC promoter methylation and age, lymph node status, and tumor number (p>0.1). APC gene was not associated with overall survival of bladder cancer patients. Our findings indicate that APC promoter methylation may be associated with the development and progression of bladder cancer and may serve as a promising non-invasive biomarker using urine samples for the detection of bladder cancer.
引用
收藏
页码：470 / +
页数：12
相关论文
共 51 条
[1]   Correlation between mutations and mRNA expression of APC and MUTYH genes: new insight into hereditary colorectal polyposis predisposition [J].
Aceto, Gitana Maria ;
Fantini, Fabiana ;
De Iure, Sabrina ;
Di Nicola, Marta ;
Palka, Giandomenico ;
Valanzano, Rosa ;
Di Gregorio, Patrizia ;
Stigliano, Vittoria ;
Genuardi, Maurizio ;
Battista, Pasquale ;
Cama, Alessandro ;
Curia, Maria Cristina .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
[2]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].
Babjuk, Marko ;
Boehle, Andreas ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Hernandez, Virginia ;
Kaasinen, Eero ;
Palou, Joan ;
Roupret, Morgan ;
van Rhijn, Bas W. G. ;
Shariat, Shahrokh F. ;
Soukup, Viktor ;
Sylvester, Richard J. ;
Zigeuner, Richard .
EUROPEAN UROLOGY, 2017, 71 (03) :447-461
[3]   EPIGENETIC ALTERATIONS OF ADENOMATOUS POLYPOSIS COLI (APC), RETINOIC ACID RECEPTOR BETA (RARβ) AND SURVIVIN GENES IN TUMOR TISSUES AND VOIDED URINE OF BLADDER CANCER PATIENTS [J].
Berrada, N. ;
Amzazi, S. ;
El Hassani, R. Ameziane ;
Benbacer, L. ;
El Mzibri, M. ;
Khyatti, M. ;
Chafiki, J. ;
Abbar, M. ;
Al Bouzidi, A. ;
Ameur, A. ;
Attaleb, M. .
CELLULAR AND MOLECULAR BIOLOGY, 2012, 58 :1744-1751
[4]   Promoter hypermethylation of tumor suppressor genes correlates with tumor grade and invasiveness in patients with urothelial bladder cancer [J].
Bilgrami, Shumaila M. ;
Qureshi, Sohail A. ;
Pervez, Shahid ;
Abbas, Farhat .
SPRINGERPLUS, 2014, 3 :1-9
[5]   Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer [J].
Brait, Mariana ;
Loyo, Myriam ;
Rosenbaum, Eli ;
Ostrow, Kimberly L. ;
Markova, Alina ;
Papagerakis, Silvana ;
Zahurak, Marianna ;
Goodman, Steven N. ;
Zeiger, Martha ;
Sidransky, David ;
Umbricht, Christopher B. ;
Hoque, Mohammad O. .
EPIGENETICS, 2012, 7 (07) :710-719
[6]   Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis [J].
Chen, Feng ;
Huang, Tao ;
Ren, Yu ;
Wei, Junjun ;
Lou, Zhongguan ;
Wang, Xue ;
Fan, Xiaoxiao ;
Chen, Yirun ;
Weng, Guobin ;
Yao, Xuping .
BMC UROLOGY, 2016, 16
[7]   Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine [J].
Chen, Pi-Che ;
Tsai, Ming-Hsuan ;
Yip, Sidney K. H. ;
Jou, Yeong-Chin ;
Ng, Chi-Fai ;
Chen, Yanning ;
Wang, Xiaoling ;
Huang, Wei ;
Tung, Chun-Liang ;
Chen, Gary C. W. ;
Huang, Martin M. S. ;
Tong, Joanna H. M. ;
Song, Eing-Ju ;
Chang, De-Ching ;
Hsu, Cheng-Da ;
To, Ka-Fai ;
Shen, Cheng-Huang ;
Chan, Michael W. Y. .
BMC MEDICAL GENOMICS, 2011, 4
[8]   P16-specific DNA methylation by engineered zinc finger methyltransferase inactivates gene transcription and promotes cancer metastasis [J].
Cui, Chenghua ;
Gan, Ying ;
Gu, Liankun ;
Wilson, James ;
Liu, Zhaojun ;
Zhang, Baozhen ;
Deng, Dajun .
GENOME BIOLOGY, 2015, 16
[9]   DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis [J].
Dai, Lihe ;
Ma, Chong ;
Zhang, Zhensheng ;
Zeng, Shuxiong ;
Liu, Anwei ;
Tang, Shijie ;
Ren, Qian ;
Sun, Yinghao ;
Xu, Chuanliang .
PLOS ONE, 2016, 11 (12)
[10]   Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel [J].
Dulaimi, E ;
Uzzo, RG ;
Greenberg, RE ;
Al-Saleem, T ;
Cairns, P .
CLINICAL CANCER RESEARCH, 2004, 10 (06) :1887-1893
123456